D-cycloserine augmented exposure therapy in patients with agoraphobia

Charité Universitätsmedizin Berlin0 个研究点开始时间: 2011年5月30日最近更新: 2014年5月12日

试验速览

暂无简介。

•- Written consent (according to § 40 AMG (1) 3 b)
•- diagnosis of agoraphobia, severity of disease according to CGI at least moderately ill
•- age: 18-75 years
•- Sufficient ability to communicate with the investigators to answer questions and fill in questionnaires or scales
•- Negative pregnancy test in premenopausal women and safe contraception during the study (defined as the Pearl Index <1)
•- accessibility of the patient (proximity) for treatment and follow-up
•- cooperation (compliance) of the patient
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•- Known overreaction after administration of DCS
•- Existing pharmacotherapy with ethionamide and / or isoniazid
•- placement in an institution of judicial or official order (according to § 40 AMG (1) 4)
•- other severe psychiatric disorders such as schizophrenia, substance dependence, dementia
•- Acute Suicidality
•- epilepsy or other diseases of the central nervous system (brain tumor, encephalitis)
•- internal diseases such as severe hypertension, de-compensated heart failure, status post acute myocardial infarction, cardiac arrhythmia of grade IV or V according to Lown, severe hepatic or renal disorders, insulin-dependent diabetes mellitus, disorders of hematopoiesis
•- Pregnancy or lactation
•- changes of a psychopharmacotherapy or discontinuation of treatment with psychotropic drugs less than 4 weeks before study
•- Short-term disturbances of the past day / night cycle
•- disorder-specific psychotherapy
•- Participation in another study within the AMG last few months before enrollment or during the partial exception of the exposure-cycloserine study
•- Lack of capacity to consent

发起方